Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants
Phase 2 N=55 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants
Phase 1 N=24 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
N/A N=221 Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4
Ovarian Tumor · Ovarian Cancer
Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001
Phase 2 N=20 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
Sarcoma
Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants
Phase 2 N=23 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
Mixed Tumor, Mullerian
Primary: Number of Participants With Overall Response — 8 participants
Phase 2 N=28 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
N/A N=62 Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Phase 2 N=47 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Leiomyosarcoma · Uterine Neoplasm
Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15
Phase 2 N=23 Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Recurrent Ovarian Cancer · Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma
Primary: Progression-free Survival Rate After 6 Months of Treatment on Study — 0 participants
Phase 2 N=32 Neoadjuvant Therapy for Ovarian Cancer
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events
Phase 2 N=20 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
Mixed Mullerian Tumors of the Uterus
Primary: Chemotherapy Completion Rate — 100 percentage of participants
Phase 2 N=25 Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Recurrent Endometrial Cancer
Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024
N/A N=7 Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation
Epithelial Ovarian Cancer
Primary: Cell Proliferation in the Fallopian Tube Fimbriae as Measured by Ki-67%+ — 8.3 percentage of positively stained cells
Phase 2 N=50 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Fallopian Tube Cancer · Ovarian Sarcoma · Ovarian Stromal Cancer
Primary: Acute Toxicity Rate — 6 percentage of participants
Phase 2 N=4 Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Ovarian Neoplasms · Fallopian Tube Neoplasms · Primary Peritoneal Neoplasms
Primary: 6 Month Progression Free Survival — 0 Participants
Phase 2 N=21 Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Participant Responses — 2; 8; 4; 6 participants
Phase 1 N=13 Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants
Phase 2 N=81 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
Uterine Cancer
Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…
Phase 2 N=13 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Response Rate — 1; 2; 4 participants
Phase 2 N=106 A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Neoplasms, Ovarian
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment — 20.0; 13.9 Percent of participants
Phase 2 N=23 Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
Phase 3 N=249 Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
Breast Cancer
Primary: Overall Survival — 2.14; 2.00 years
Phase 2 N=61 Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Endometrial Cancer
Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months
Phase 2 N=31 MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Ovarian Carcinoma
Primary: Combined Best Overall Response Rate Based on Investigator Assessment — 0; 12 percentage of participants
Phase 2 N=30 Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
Uterine Cancer
Primary: Cycles With Hematologic Toxicities — 11; 14; 6; 0 Cycles
Phase 2 N=62 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Ovarian Cancer
Primary: PFS — 29.8 Months
Phase 1 N=9 Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Tolerated Dose — 80 mg/m^2
N/A N=150 Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Fallopian Tube Cancer · Ovarian Cancer · Ovarian Neoplasms
Primary: Sensitivity and Specificity of Cytological Samples for Fallopian Tube Involvement — .143; .959 Proportion of Cytuity Cell Samples